• Lihua Hong, Jian Zhang, and Jianguo Shen.
• Department of Endocrinology, The First Affiliated Hospital of Zhejiang University School of Medicine, 79# Qingchun Road, Hangzhou, Zhejiang Province, PR China 310003; Lin'an People's Hospital, 548# Yijin Road, Jincheng Town, Lin'an, Hangzhou, Zhejiang Province, PR China 311300.
• J. Diabetes Complicat. 2015 Nov 1; 29 (8): 1283-6.

ObjectiveTo observe the clinical efficacy of different doses of alprostadil (lipo-prostaglandin E1, lipo-PGE1) in the treatment of painful diabetic peripheral neuropathy (DPN).MethodsSixty patients with painful DPN were equally and randomly assigned into three groups. Two groups received different doses of lipo-PGE1 by intravenous drip injection (A group: low-dose lipo-PGE1; B group: high-dose lipo-PGE1) following intravenous bolus injection of mecobalamin (MeCbl, 0.5mg once daily (QD)); the third group received MeCbl alone (C group). All patients received optimized treatment to lower blood glucose, blood pressure, and blood lipids to target levels. The efficacy of lipo-PGE1 in the three groups of patients was observed after 3weeks of treatment.ResultsThe overall response rate was 90% in the B group, significantly higher than that in the A and C groups (80% and 55%, respectively; P<0.05). During the observation period, there was no incidence of serious adverse reactions (e.g., acute heart failure, sudden drop in blood pressure, or malignant arrhythmias) in any of the three groups.ConclusionsHigh-dose lipo-PGE1 has better efficacy than low-dose lipo-PGE1 or MeCbl alone in the treatment of painful DPN.Copyright © 2015 Elsevier Inc. All rights reserved.

59 keywords...

hide…